🟢 20/20 Biolabs is trading 5% up — no confirmed company-specific catalyst

20/20 Biolabs is trading 5.26% higher at $0.40, up from its October 2 close of $0.38; no company-specific catalyst is confirmed.

• An October 2 announcement said CEO and CFO will meet institutional investors at the October 14 Maxim Growth Summit; this is not a confirmed cause.
• A Maxim Group Buy rating was reported October 3; an October 7 investor webinar is upcoming. Neither is confirmed as the driver.
• Broader indices are mixed; no market-wide link is clear.